J. Roca (Barcelona, Spain), E. F. M. Wouters (Maastricht, The Netherlands)
Adherence of stable COPD patients to inhaled pharmacotherapy
S. Dumitru, K. Velentzas, E. Theodorakopoulou, M. Harikiopoulou, M. Andritsou, A. Chronaiou, Z. Sardelis, E. Kainis, P. Demertzis, E. Kosmas (Athens, Greece)
|   |
Health-related quality of life (HRQL) and patient-reported outcomes (PRO) in COPD patients receiving add-on-therapy with EPs® 7630
H. Matthys, D. Pliskevich, T. Reineke, F. A. Malek (Freiburg i. Br., Karlsruhe, Germany; Kiev, Ukraine)
| |
Treatment with megestrol acetate and testosterone increases body weight and muscle mass in COPD cachexia
R. Casaburi, J. Nakata, L. Bistrong, E. Torres, M. Rambod, J. Porszasz (Torrance, United States Of America)
| |
Efficacy of roflumilast in former and current smokers with COPD
P. Calverley, U. M. Goehring, F. Martinez, N. Barnes (Liverpool, London, United Kingdom; Konstanz, Germany; Ann Arbor, United States Of America)
| |
Impact of roflumilast treatment on the rate and duration of exacerbations and overall steroid load in patients with COPD
P. Calverley, F. Martinez, U. M. Goehring, D. Bredenbröker, M. Brose, C. Vogelmeier (Liverpool, United Kingdom; Ann Arbor, United States Of America; Konstanz, Marburg, Germany)
| |
Acupuncture improves nutritional status and BODE index in patients with chronic obstructive pulmonary disease: A randomized, placebo-controlled trial
M. Suzuki, M. Fukui, T. Shiota, K. Endo, S. Sato, K. Aihara, M. Matsumoto, S. Suzuki, R. Itotani, M. Ishitoko, M. Takemura, Y. Hara, H. Kagioka, M. Hirabayashi, S. Muro, M. Mishima (Kyoto, Osaka, Hyogo, Japan)
| |
Time to desaturation under 1 minute on the 6m walking test predicts chronic domiciliary oxygen therapy in COPD patients
L. Eiroa, R. Pitti, J. M. Palmero, J. M. Figueira, A. I. Velázquez, M. Alonso, J. Rodríguez, C. Ramos, I. De Lorenzo, J. L. Trujillo, A. Tauroni, I. García Talavera (Santa Cruz de Tenerife, Spain)
| |
Tiotropium vs salmeterol in GOLD II and maintenance-naïve COPD patients: Subgroup analyses of POET-COPDÔ trial
K. M. Beeh, C. Vogelmeier, M. P. M. H. Rutten-van Mölken, K. F. Rabe, T. Glaab, F. Rühmkorf, H. Schmidt, L. M. Fabbri (D 65187 Wiesbaden, Marburg, Grosshansdorf, Ingelheim, Germany; Rotterdam, Netherlands; Modena, Italy)
| |
Efficient deposition and absorption of orally inhaled indacaterol in the lungs
R. Lock, D. Price, S. Khindri, R. Woessner, M. Weiss, H. Hara, I. Pylvaenaeinen, G. Kaiser (Horsham, United Kingdom; Basel, Switzerland)
| |
Subclinical cardiac dysfunction in moderate to severe chronic obstructive pulmonary disease (COPD) patients
A. Verduri, B. Bottazzi, C. Leuzzi, R. D‘Amico, P. Boschetto, M. G. Modena, A. Mantovani, L. M. Fabbri, B. Beghé (Modena, Milan, Ferrara, Italy)
| |
Effects of ambulatory oxygen on exercise capacity and vital parameters in patients with COPD
B. Yilmaz, E. Yentürk, D. Yenibertiz, F. Atabey, E. Tuncay (Istanbul, Turkey)
| |
Time required for PaO2 equilibration in patients with severe COPD
L. P. Thomsen, S. Rees, U. Weinreich (Aalborg, Denmark)
| |
Determinants of dyspnea in stable COPD patients
T. Perez, J. L. Paillasseur, P. R. Burgel, N. Roche, on Behalf the Initiatives BPCO Group (Lille, Clamart, Paris, France)
| |
Screening for malnutrition in outpatients with pulmonary diseases
S. Schokker, J. S. Vroegop, L. H. Steenhuis, R. Aalbers (Groningen, Netherlands)
| |
Comparison of costs of community-acquired pneumonia (CAP) treatment at patients with and without bronchial obstruction
Y. Mostovoy, H. Demchuk (Vinnytsia, Ukraine)
| |
Comorbidities in stage IV COPD patients
V. Areias, S. Carreira, M. Anciães, P. Pinto, C. Bárbara (Lisboa, Faro, Portugal)
| |
Fenspiride as complementary anti-inflammatory agent in therapy of patients with chronic obstructive pulmonary disease
T. Pertseva, O. Myronenko, N. Klimenko (Dniprppetrovsk, Ukraine)
| |
What are the factors related to misdiagnosis of COPD?
J. Bourbeau, D. O‘Donnell, F. Maltais, D. Marciniuk, A. Benedetti, S. Aaron, K. Chapman, R. Cowie, M. Fitzgerald, P. Hernandez, D. Sin, W. Tan, For CanCOLD Study Group (Montreal, Kingston, Quebec, Saskatoon, Ottawa, Toronto, Calgary, Halifax, Vancouver, Canada)
| |